Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2022-07-21 Call Transcript
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 29th July, 2022 at 07:30 P.M. to discuss the financial performance of the Company for the quarter ....
Call Transcript Classification · 95% confidence The document is a notification about a scheduled teleconference (conference call) with investors and analysts to discuss the financial performance for the quarter ended June 30, 2022. It provides dial-in information and contact details but does not contain any financial data or results itself. This matches the characteristics of a Call Transcript announcement or a Call Schedule notice. Since it is announcing a conference call related to quarterly financial results, the appropriate classification is Call Transcript (CT). The document length is short and it is not a report or financial statement itself, so it is not an Interim Report or Earnings Release. Therefore, the best fit is CT with high confidence.
2022-07-21 English
This has reference to the article published in Business Standard on July 20, 2022 with title "Torrent Pharma expected to enter diagnostics space in next 2-3 months". We would like to ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the listing department of BSE and NSE, clarifying a news article about the company's investment activities. It is a short communication (1333 characters) that provides a clarification statement rather than financial data, management changes, or regulatory filings. It does not contain financial results, audit information, or meeting materials. It is not a report but a regulatory announcement clarifying a market rumor. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-21 English
General updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the listing department of BSE Limited, clarifying a news article about the company's investment activities. It explicitly states that Torrent Pharma has not made investments into a certain entity, correcting misinformation. The document is short (1333 characters) and serves as a clarification or regulatory announcement rather than a financial report or detailed filing. It does not contain financial data, management discussion, or any report content. It is not an announcement of voting results, board changes, or capital changes. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement clarifying a public statement.
2022-07-21 English
Bonus
Share Issue/Capital Change Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing about the allotment of bonus equity shares by the company. It details the number of shares allotted, the ratio of allotment, the increase in paid-up share capital, and clarifies dividend rights related to the bonus shares. There is no financial statement, management discussion, or detailed report content. The document is an announcement regarding a capital change event (bonus share allotment). Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short and it is not a report publication or certification, so it is not RPA or RNS. Hence, the classification is SHA with high confidence.
2022-07-13 English
In furtherance to our letter dated 25-May-22, we would like to inform that the Company has allotted 16,92,22,720 Bonus equity shares of Rs. 5/- each on Wednesday, 13-Jul-22. The shares ....
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the allotment of bonus equity shares by the company. It details the number of shares allotted, the ratio of allotment, the increase in paid-up share capital, and clarifies dividend rights related to the bonus shares. There is no financial statement, earnings data, or management discussion. The content is an announcement about a capital change event (bonus shares allotment). Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is short and focused on this specific corporate action, confirming the classification.
2022-07-13 English
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2022 ,inter alia, to consider and approve We would like to inform ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the date of an upcoming Board Meeting where audited and unaudited financial results will be considered and approved. It is an intimation under SEBI regulations about a future event, not the financial results themselves. The document length is only 1353 characters, indicating it is a brief announcement rather than a full report. According to the 'Menu vs Meal' rule, such short notices about upcoming reports or meetings are classified as Regulatory Filings (RNS), not as the actual financial reports (like IR or 10-K).
2022-07-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.